Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study

Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Related Videos
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Evan Y. Yu, MD, professor, medical oncology, assistant fellowship director, University of Washington School of Medicine, professor, Clinical Research Division, clinical research director, Genitourinary Medical Oncology, Fred Hutchinson Cancer Center, medical director, clinical research support, Fred Hutchinson Cancer Research Consortium
Michael A. Carducci, MD, professor of oncology, AEGON Professor of Prostate Cancer Research, Johns Hopkins Medicine
Michael S. Cookson, MD, MMHC, professor, chairman of urology, University of Oklahoma College of Medicine, chief, Urology, Stephenson Cancer Center
Andrei H. Iagaru, MD, professor of Radiology - Nuclear Medicine, chief, Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center
Jeremie Calais, MD, MSc, assistant professor of nuclear medicine and theranostics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), UCLA Health,
Tanya Dorff, MD, medical oncologist, associate clinical professor, Department of Medical Oncology & Therapeutics Research, City of Hope
Matthew Rettig, MD, chief, hematology-oncology, VA Medical Center, professor of medicine and urology, David Geffen School of Medicine, University of California, Los Angeles (UCLA) Health
Expert on urothelial carcinoma
Tian Zhang, MD, MHS
Related Content

Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors

March 24th 2023

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15th 2022

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors

March 24th 2023

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15th 2022

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors

March 24th 2023

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15th 2022

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023